FDA-fast-track-designation-chronic-heart-failure

US FDA grants Fast Track designation to empagliflozin for the treatment of chronic heart failureFast Track designation facilitates the development of new therapies that treat serious conditions and fulfill an unmet medical need.  FDA ’s Fast Track designation for empagliflozin underscores the urgent need for new potential treatment options for the 26 million people affected by chronic heart failure worldwide, including 6.5 million in the US.1,2
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news